<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00767481</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-16</org_study_id>
    <secondary_id>2008-002781-66</secondary_id>
    <nct_id>NCT00767481</nct_id>
  </id_info>
  <brief_title>1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parallel, Multi-Center, Double-masked, Active controlled, three arm study comparing the IOP
      lowering efficacy and safety over 12 months of morning or evening instillations of
      Travoprost/Brinzolamide vs. Cosopt dosed in the morning and evening in patients with
      open-angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Project Cancelled
  </why_stopped>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP</measure>
    <time_frame>9:00,11:00, and 1600 time points at month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in IOP, IOP change from baseline, patients with IOP &lt;18mmHg. BSCVA, Ocular signs, Dilated fundus, perimetry, pachymetry, cardiovascular parameters(pulse, BP and AEs at W2, W3, M6, M9 and M12.</measure>
    <time_frame>All on therapy time points not included in primary efficacy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Travoprost/Brinzolamide PM, Vehicle AM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost/Brinzolamide PM, Vehicle AM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost/Brinzolamide AM, Vehicle PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost/Brinzolamide AM, Vehicle PM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cosopt</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cosopt BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost/Brinzolamide</intervention_name>
    <description>Eye drop suspension, once daily</description>
    <arm_group_label>Travoprost/Brinzolamide PM, Vehicle AM</arm_group_label>
    <arm_group_label>Travoprost/Brinzolamide AM, Vehicle PM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosopt</intervention_name>
    <description>Eye drop solution, one drop BID</description>
    <arm_group_label>Cosopt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IOP at screening visit &lt;18mmHg in at least one eye Mean IOP in same eye (at both
             eligibility 1 &amp;2 visits)

               -  24 and ≤ 36 mmHg at 9:00

               -  21 and ≤ 36 mmHg at 11:00 and 16:00

        Exclusion Criteria:

          -  Severe central visual field loss Angle Shaffer grade &lt; 2 C/D ratio &gt; 0.8 (horizontal
             or vertical measurement)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2008</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>Patients with open-angle glaucoma or ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

